Ritlecitinib in CTCL

NCT05879458 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped No significant improvement in disease as graded by our assessments.

Conditions

CTCL
Mycosis Fungoides
Sezary Syndrome

Interventions

DRUG: Ritlecitinib

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]